Ruxolitinib for myelofibrosis

By                  

Experimental and Therapeutic Medicine, Vol. 5, Iss. 3, 2013-01 ,pp. : 927-931

Spandidos Publications

Access to resources Recommend Favorite

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

By Braganca Kevin   Janjigian Yelena   Azzoli Christopher   Kris Mark   Pietanza Maria   Nolan Craig   Omuro Antonio   Holodny Andrei   Lassman Andrew  

Journal of Neuro-Oncology, Vol. 100, Iss. 3, 2010-12 ,pp. : 443-447

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab (Avastin®)

By Shimoyama Tatsu  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 523-530

Sunmedia

Access to resources Recommend Favorite

Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: A systematic review and meta-analysis

By          

Experimental and Therapeutic Medicine, Vol. 7, Iss. 6, 2014-01 ,pp. : 1663-1670

Spandidos Publications

Access to resources Recommend Favorite

Myelofibrosis in primary myelodysplastic syndromes: Clinical and Biological Significance

By Marisavljević D.   Rolović Z.   Ćemerikić V.   Bošković D.   Ćolović M.  

Medical Oncology, Vol. 21, Iss. 4, 2004-12 ,pp. : 325-331

Humana Press, Inc

Access to resources Recommend Favorite